Contact: Vicki Cohn, (914) 740-2156, firstname.lastname@example.org
Human Embryos Frozen for 18 Years Yield Viable Stem Cells Suitable for Biomedical Research
New Rochelle, NY, August 13, 2012—Even after being frozen for 18 years, human embryos can be thawed, grown in the laboratory, and successfully induced to produce human embryonic stem (ES) cells, which represent a valuable resource for drug screening and medical research. Prolonged embryonic cryopreservation as an alternative source of ES cells is the focus of an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free online at the BioResearch Open Access website.
Kamthorn Pruksananonda and coauthors from Chulalongkorn University and Chulalongkorn Memorial Hospital, Bangkok, Thailand, demonstrated that ES cells derived from frozen embryos have a similar ability to differentiate into multiple cell types—a characteristic known as pluripotency—as do ES cells derived from fresh embryos. They present their findings in the article “Eighteen-Year Cryopreservation Does Not Negatively Affect the Pluripotency of Human Embryos: Evidence from Embryonic Stem Cell Derivation.”
“The importance of this study is that it identifies an alternative source for generating new embryonic stem lines, using embryos that have been in long-term storage," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.
About the Journal
BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website.
About the Publisher
Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website.